The trend toward outsourcing pharmaceutical development and manufacturing has accelerated during COVID as pharma companies — both in the US and abroad — seek to streamline their own facilities, focus on core competencies and avoid product delays inherent in overseas manufacturing. Partnering with a CDMO allows them to access more specialized knowledge, state-of-the-art equipment and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market. As both a CDMO and a manager of CMOs, Avéma Pharma Solutions sees a number of trends emerging that CDMOs must embrace to be successful including:

• • More strategic, integrated relationships

• • Narrower product focus

• • Emphasis on development

• • End-to-End support and manufacturing flexibility

• • Re-evaluating supply chain management

• • Manufactured in the USA

• • Continuous reinvestment

• • Consultive relationships